Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
| ▸ | HTR7 | P34969 | 15/20 | 0.55 |
| ▸ | HTR2A | P28223 | 1/20 | 0.52 |
| ▸ | HTR2C | P28335 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18896601 | 0.85 | HTR7 (0.46) | MAPTHTR7HTR2C | |
| SCHEMBL19200998 | 0.85 | PDE10A (0.48) | HTR7 | |
| SCHEMBL14114993 | 0.85 | LMNA (0.64) | — | |
| SCHEMBL7147056 | 0.82 | PDE10A (0.60) | HTR7 | |
| SCHEMBL15164727 | 0.81 | PDE10A (0.69) | HTR7 | |
| SCHEMBL27592014 | 0.80 | PDE10A (0.57) | MAPT | |
| SCHEMBL15819453 | 0.79 | PDE10A (0.50) | — | |
| SCHEMBL14115045 | 0.79 | MEN1 (0.61) | MAPT | |
| SCHEMBL17586324 | 0.79 | PIK3CD (0.52) | NPC1RAB9A | |
| SCHEMBL17586323 | 0.78 | PIK3CD (0.50) | NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210332047-A1 | QUINAZOLINONES AS INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | ICOS CORP (US) | 2021-10-28 | — | — | US | disclosed |
| US-10336756-B2 | (S)-2-(1-aminopropyl)-5-fluoro-3-phenylquinazolin-4(3H)-one precursor of a quinazolinone as inhibitor of human phosphatidylinositol 3-kinase delta | ICOS CORPORATION (US) | 2019-07-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10336756-B2 | (S)-2-(1-aminopropyl)-5-fluoro-3-phenylquinazolin-4(3H)-one precursor of a quinazolinone as inhibitor of human phosphatidylinositol 3-kinase delta | PIK3CD, PIK3CA, PI4KA | MAPT 4691/4885HTR7 1392/4885HTR2A 2091/4885 |
| US-20210332047-A1 | QUINAZOLINONES AS INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | PIK3CD, PIK3CA, PI4KA | MAPT 4423/4885HTR7 2199/4885HTR2A 3692/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.